Publications by authors named "Craig D Fisher"

Claim this Profile
I
Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage.
Francis S Wolenski, Pooja Shah, Tomoya Sano, Tadahiro Shinozawa, Hugues Bernard, Craig D Fisher

J Appl Toxicol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
Rhiannon N Hardwick, Craig D Fisher, Stephanie M Street, Mark J Canet, Nathan J Cherrington

Drug Metab Dispos· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease.
Rhiannon N Hardwick, Craig D Fisher, Mark J Canet, George L Scheffer, Nathan J Cherrington

Drug Metab Dispos· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease.
April D Lake, Petr Novak, Craig D Fisher, Jonathan P Jackson, Rhiannon N Hardwick

Drug Metab Dispos· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.
Rhiannon N Hardwick, Craig D Fisher, Mark J Canet, April D Lake, Nathan J Cherrington

Drug Metab Dispos· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.
Craig D Fisher, Andrew J Lickteig, Lisa M Augustine, James Ranger-Moore, Jonathan P Jackson

Drug Metab Dispos· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats.
Craig D Fisher, Andrew J Lickteig, Lisa M Augustine, Ronald P J Oude Elferink, David G Besselsen

Eur J Pharmacol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.
Craig D Fisher, Jonathan P Jackson, Andrew J Lickteig, Lisa M Augustine, Nathan J Cherrington

Arch Toxicol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats.
Lisa M Augustine, Craig D Fisher, Andrew J Lickteig, Lauren M Aleksunes, Angela L Slitt

J Biochem Mol Toxicol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Nrf2 activator oltipraz also activates the constitutive androstane receptor.
Matthew D Merrell, Jonathan P Jackson, Lisa M Augustine, Craig D Fisher, Angela L Slitt

Drug Metab Dispos· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis.
Andrew J Lickteig, Craig D Fisher, Lisa M Augustine, Nathan J Cherrington

J Biochem Mol Toxicol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.
Andrew J Lickteig, Craig D Fisher, Lisa M Augustine, Lauren M Aleksunes, David G Besselsen

Drug Metab Dispos· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of drug-metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2.
Craig D Fisher, Lisa M Augustine, Jonathan M Maher, David M Nelson, Angela L Slitt

Drug Metab Dispos· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of fear of hypoglycemia in adolescents with type 1 diabetes and their parents.
Linda A Gonder-Frederick, Craig D Fisher, Lee M Ritterband, Daniel J Cox, Likun Hou

Pediatr Diabetes· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-class pan caspase inhibitor developed for the treatment of liver disease.
Steven D Linton, Teresa Aja, Robert A Armstrong, Xu Bai, Long-Shiuh Chen, Craig D Fisher

J Med Chem· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethical issues in therapy: therapist self-disclosure of sexual feelings.
Craig D Fisher

Ethics Behav· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor.
Niel C Hoglen, Long-Shiuh Chen, Craig D Fisher, Brad P Hirakawa, Todd Groessl

J Pharmacol Exp Ther· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis